ZoomInfo Technologies Inc. (NASDAQ: ZI) shares are 9.44% up in the year-to-date (YTD) period and have moved 0.49% or $0.18 higher in the latest trading session. If we look at the shorter duration, its week performance is 1.03% and -8.08% over the month.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
On June 29, 2020, Wells Fargo recommended the ZI stock is a Equal Weight, while earlier, Deutsche Bank had Initiated the stock as a Hold on June 30, 2020. 16 analysts offering the recommendations for the stock have a consensus rating of 2.40 to suggest that the ZI stock is a “Moderate Buy. 0 of the 16 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 6 recommend buying, with 1 rating it as an Overweight.
The stock currently trades at $37.21 and analysts tracking its performance over the next 12 months have a consensus estimate price target of $53.79. The forecasts give the ZoomInfo Technologies Inc. stock a price target range of $63.00 on the higher side while at least one analyst think the stock could plunge to a low of $45.00. The two limits represent an upside potential of 40.94% or 17.31%.
Analysts also offered guidance for the next financial quarter, with their average projected EPS at between $0.08 and $0.11. Wall Street estimates earnings per share to be at an average of $0.45 for the next year.
Insider Transactions Summary
According to SEC data, total insider shares purchases at the company stands at 10 over the last 12 months, while SEC filings reveal that there have been 10 insider sales over the same period. Insiders have purchases 8,197,378 shares while those sold by company executives and officers stand at 8,197,378. The last 3 months have seen insiders trade a total of 8,197,378 and 8,197,378 in purchases and sales respectively.
TA Atlantic & Pacific VII-B L., a Director at the company, sold 8,197,378 shares worth $293.45 million at $35.80 per share on Aug 24. The Director had earlier sold another 8,197,378 ZI shares valued at $293.45 million on Aug 24. The shares were sold at $35.80 per share. Crockett Todd (Director) sold 8,197,378 shares at $35.80 per share on Aug 24 for a total of $293.45 million while Mironov Jason, (Director) sold 8,197,378 shares on Aug 24 for $293.45 million with each share fetching $35.80.
Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS), on the other hand, is trading around $0.29 with a market cap of $50.41M and analyst research firms have a positive stance on its shares. Some analysts are even forecasting -$0.16 per share in earnings this year on a short term (1 year) basis.
Let us briefly look at the Sunesis Pharmaceuticals Inc. (SNSS) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.
Company balance sheet and cash flow
SNSS’s operating expenses over the recent quarter were at -$6.34 million. With this in place, we can see that the company’s diluted EPS declined -$0.06 on the year-over-year period, shrinking to -$0.09 as given in the last earnings report.
In terms of the balance sheet & cash flow as of (Sep 2020), the total assets figure advanced to $25.51 million from $31.49 million over the previous quarter. The company’s free cash flow for the quarter was -$11.54 million.
Insiders have transacted a total of 1 times at Sunesis Pharmaceuticals Inc. over the last 6 months, with insider purchases undertaken 1 times and accounting for 6,000 shares. Insider sales totaled 0 shares over the same period, with these deals completed in 0 transactions. Looking at these numbers, we realize that net purchases over that period are 1.0 shares. Insiders now hold a total of 325.68k shares after the latest sales, with 3.80% net shares purchased.
Insiders own 0.18% of the company shares, while shares held by institutions stand at 24.60% with a share float percentage of 65.91M. Investors are also buoyed by the number of investors in a company, with Sunesis Pharmaceuticals Inc. having a total of 56 institutions that hold shares in the company.